Modern tactics of treatment of tumor pericarditis
https://doi.org/10.18027/2224-5057-2017-3-57-61
Abstract
Pericarditis in cancer patients occures in the late stage of the disease and in 95% of cases is caused by metastases of lung, breast, gastrointestinal cancer and hemoblastosis. Malignant exudate in the pericardial cavity in half cases leads to tamponade of the heart and death of the patient. The actual goal in modern oncology is to find the most effective and low-toxic treatment of pericardial carcinomatosis and tumor pericarditis. One of the effective methods of treating of this category of patients is intrapericardial immunotherapy with IL-2.
About the Authors
K. S. Titov
Moscow Clinical Scientific Center;
N.I. Pirogov Russian National Research Medical University
Russian Federation
MD, PhD, Head of the Оnсоsurgery Department of Tumors of Skin and Soft Tissues, Moscow Clinical Scientific Center; Associate Professor of the Department of Oncology and Radiation Therapy of the Faculty of Medicine, N.I. Pirogov Russian National Research Medical University
Russian Federation
MD, PhD, Head of the Оnсоsurgery Department of Tumors of Skin and Soft Tissues, Moscow Clinical Scientific Center; Associate Professor of the Department of Oncology and Radiation Therapy of the Faculty of Medicine, N.I. Pirogov Russian National Research Medical University
M. V. Kiselevsk
N. N. Blokhin Russian Cancer Research Center
Russian Federation
MD, PhD, Professor, Head of the Laboratory of Cellular Immunity
Russian Federation
MD, PhD, Professor, Head of the Laboratory of Cellular Immunity
References
1. Титов К. С., Демидов Л. В., Шубина И. Ж., Грицай А. Н., Егорова А. В., Киселевский М. В. Клиническая эффективность внутриполостной биотерапии у больных с опухолевыми серозитами // Российский онкологический журнал. 2015. № 2. С. 8–12. [Titov K. S., Demidov L. V., Choubina I. Zh., Gritsay A. N., Egorova A. V., Kiselevsky M. V. Clinicаl efficiency of intracavitary biotherapy at patients with tumoral serozita, Russian oncological magazine, 2015, No. 2, pp. 8–12 (In Russ.)].
2. Титов К. С., Киселевский М. В., Сельчук В. Ю., Грицай А. Н., Анисимова Н. Ю. Внутриперикардиальная иммунотерапия опухолевых перикардитов // Сибирский медицинский журнал. 2011. № 5. С. 47–52. [Titov K. S. Kiselevsky M. V., Selchuk V. Yu., Gritsay A. N., Anisimova N. Yu. Intra pericardiac immunotherapy of tumoral perikardit // Siberian medical magazine, 2011, No. 5,
3. pp. 47–52 (In Russ.)].
4. Abeel. A., Mangi D. F. Torchiana Pericardial Disease Card, Surg. Adult, 2008, Vol. 3, pp. 1465–1478.
5. Baba M., Yamaguchi Y., Fujisawa Y. T. et al. The effects of localized therapy with postsurgical local recurrences of lung carcinoma and metastatic lung tumors-laser irradiation, IL-2+ LAK or ethanol injection, Gan. To Kagaku Ryoho, 1988, Vol. 15, No. 4 (Pt. 2), pp. 1342–1350.
6. Buzaid A. C., Garewal H. S., Greenberg B. R. Managing malignant pericardial effusion, West J. Med., 1989, Vol. 150, pp. 174–179.
7. Callahan J. A., Sevard J. B., Nishimura R. A. et al. Two-dimensional echocardioraphically guided pericardiocentesis experiens in 117 consecutive patients, Am. J. Cardiol., 1985, Vol. 55, pp. 476–479.
8. Chen Y. Q., Shi H. Z., Qin X. J. et al. CD4+CD25+ Regulatory T Lymphocytes in Malignant Pleural Effusion, Am. J. Respir. Crit. Care Med., 2005, Vol. 172, pp. 1434–1439.
9. Janes S. M., Rahman N. M., Davies R. J. Catheter-tract metastases associated with chronic indwelling pleural catheters, Chest., 2007, Vol. 131, No. 4, pp. 1232–1234.
10. Liepman M. K., Goodlerner S. Surgical management of pericardial tamponade as a presenting manifestation of acute leukemia, J. Surg. Oncol., 1981, Vol. 17, pp. 183–188.
11. Li Y., Meng F. D., Tian X., Sui C. G., Liu Y. P., Jiang Y. H. Impact of IL-2 and IL-2R SNPs on proliferation and tumor- killing activity of lymphokine-activated killer cells from healthy chinese blood donors, Asian Pac J. Cancer Prev., 2014, Vol. 15, pp. 7965–7970.
12. Liepman M. K., Goodlerner S. Surgical management of pericardial tamponade as a presenting manifestation of acute leukemia, J. Surg. Oncol., 1981, Vol. 17, pp. 183–188.
13. Lund R. H., Newkirk J. B. Peritoneovenous shunting system for surgical management of ascites, Contemp. Surg., 1979, Vol. 14, pp. 31–45.
14. Maher E. R., Buckman R. Intrapericardial installation of bleomycin in malignant pericardial effusion, Am. Heart. J., 1986, Vol. 111, pp. 613–614.
15. Mufti G. J., Oscier D. G., Hamblin T. J. et al. Serous effusion in monocytic leukemias, Br. J. Haematol., 1984, Vol. 58, pp. 547–552.
16. Mulvagh S. L., Rokey R., Vick G. W. et al. Usefulness of nuclear magnetic resonance imaging for evaluation of pericardial effusions, and comparison with two-dimensional echocardiography, Am. J. Cardiol., 1989, Vol. 64, pp. 1002–1009.
17. Polyzos A., Tasvaris N., Kosmas C. et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer, A. Polyzos. Oncol., 1999, Vol. 56, pp. 291–296.
18. Sagristа-Sauleda J., Mersy J., Permanyer-Miralda G. et al. Clinical clues to the causes of large pericardial effusions, Am. J. Med., 2000, Vol. 109, pp. 95–101.
19. Sahin U., Unlu M., Akkaya A. et al. The value of small-bore catheter thoracostomy in the treatment of malignant pleural effusions, Respiration, 2001, Vol. 68, No. 5, pp. 501–505.
20. Shibata M., Gonda K., Kumamoto K. Immunological cell therapy, 2014, Vol. 72, pp. 42–48.
21. Shield P. W., Callan J. J., Devine P. L. Markers for metastatic adenocarcinoma in serous effusion specimens, Diag. Cytol, 1994. Vol. 11, pp. 237–245.
22. Sun J. S., Law G.P., McKallip R.J. Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma, Cancer Immunol. Immunother. 2012, Vol. 61, pp. 323–334.
23. Taylor A., Bailey N. A., Halpern S. E. et al. Loculation as a contraindication to intracavitary 32P- chromic phosphate therapy, J. Nucl. Med., 1975, Vol. 16, pp. 318–319.
24. Thomason R., Schlegel W., Lucca M. et al. Primary malignant mesothelioma of the pericardium. Case report and literature review, Tex. Heart. Inst. J., 1994, Vol. 2, pp. 170–174.
25. Thompson R. L., Yau J. C., Donnelly R. J. et al. Pleurodesis with iodized talc for malignant effusion using pigtail catheter, Ann. Pharmacother., 1998, Vol. 32, No. 7, pp. 739–742.
26. Toorn L. M., Schaap E., Surmont V. F. et al. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter, Lung. Cancer, 2005, Vol. 50, No. 1, pp. 123–127.
27. Tremblay A., Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion, Chest, 2006, Vol. 129, No. 2, pp. 362–368.
28. Van Cutsem E., Moiseyenko V. M., Tjulandin S. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as firstline therapy for advanced gastric cancer: a report of the V325 Study Group, J. Clin. Oncol., 2006, Vol. 24, pp. 4991–4997.
29. Vergote I. B., Winderen M., De Vos L. N. et al. Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma; analysis of 313 patients treated primarily or at second-look laparatomy, Cancer, 1993, Vol. 71, pp. 2250–2260.
30. Wheeldon E. B., Mariassay A. T. The pleura: A combined light microscopic, scanning and transmission electron microscopic study in the sheep. II Response to injury, Exp. Lung. Res., 1983, Vol. 5, pp. 125–140.
31. Witkowicz J. Mesothelial cell transplantation, Pol. Arch. Med. Wewn., 2008, Vol. 118, No. 5, pp. 307–313.
32. Yunoki K., Naruko T., Ohashi J. et al. Primary effusion lymphoma complicating cardiac tamponade: a case report, J. Cardiol., 2007, Vol. 49, pp. 205–210.
33. Zebrowski B., Liu W., Ramirez K. et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites, Ann. Surg. Oncol., 1999, Vol. 6, No. 4, pp. 373–378.
Review
For citations:
Titov K.S., Kiselevsk M.V. Modern tactics of treatment of tumor pericarditis. Malignant tumours. 2017;(3):57-61. (In Russ.) https://doi.org/10.18027/2224-5057-2017-3-57-61
Views:
2267
Email this article 